Our AI-driven drug discovery platform identifies protein hits with high docking scores and evaluates ADMET properties at the early stage of drug development. For more information, please contact us via email.
Our AI-driven drug discovery platform accelerates and de-risks the early stages of pharmaceutical research by integrating advanced computational modeling with machine learning. The system not only identifies promising protein–ligand interactions with high docking scores, but also simultaneously evaluates ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. By combining virtual screening, molecular dynamics, and predictive toxicology into a unified workflow, our platform enables researchers to prioritize candidates with both strong binding affinity and favorable pharmacokinetic profiles. This early-stage filtration helps reduce downstream failures, shortens development timelines, and optimizes R&D investments.
For more information or collaboration inquiries, please contact us via email.
For more information or collaboration inquiries, please contact us via email.